Natalizumab in Multiple Sclerosis: Long-Term Management

Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Despite its effectiveness, there are growing concerns regarding the risk of progressive multifocal leukoencephalopathy (PML), a brain infection caused by John Cunningham virus (JCV), particularly after 24 doses and in patients who previously received immunosuppressive drugs. Long-term natalizumab treated, immunosuppressive-pretreated, and JCV antibody-positive patients are asked to rediscuss natalizumab continuation or withdrawal after 24 doses. Until now, there has not been a clear strategy that should be followed to avoid PML risk and in parallel reduce clinical and radiological rebound activity. In this review, we analyzed the results of clinical trials and case reports in relation to the following situations: natalizumab continuation, natalizumab discontinuation followed by full therapeutic suspension or switch to other first or second line MS treatments. Quitting all MS treatment after natalizumab increases MS activity occurrence. The results regarding the therapeutic switch are not homogeneous, so at the moment there are no established guidelines regarding natalizumab treatment after 24 administrations; the choice is currently based on the professional experience of the neurologist, and on patients’ clinical features and preferences.

[1]  J. M. Scholtz,et al.  Osteopontin is a ligand for the alpha4beta1 integrin. , 1998, Journal of cell science.

[2]  U. de Girolami,et al.  Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual , 2003, Neurology.

[3]  X. Montalban,et al.  Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab , 2012, Multiple sclerosis.

[4]  I. Koralnik,et al.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis , 2010, The Lancet Neurology.

[5]  C. Pozzilli,et al.  Pulse monthly steroids during an elective interruption of natalizumab: a post‐marketing study , 2012, European journal of neurology.

[6]  G. Koren,et al.  Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study , 2015, Multiple sclerosis.

[7]  I. Yakoub-Agha,et al.  Immunosuppressive drugs and fertility , 2015, Orphanet Journal of Rare Diseases.

[8]  C. Leone,et al.  Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report , 2015, BMC Neurology.

[9]  F. Sperli,et al.  High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study , 2016, Neurology and Therapy.

[10]  A. Minagar.  Natalizumab Drug Holiday in Multiple Sclerosis: Poorly Tolerated , 2011 .

[11]  A. Synnes,et al.  Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review , 2013, Neurology.

[12]  S. Realmuto,et al.  Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers , 2015, Neurology and Therapy.

[13]  E. Major,et al.  Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. , 2002, The Journal of infectious diseases.

[14]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[15]  C. Pozzilli,et al.  Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. , 2015, Brain : a journal of neurology.

[16]  E. Richardson,et al.  Progressive multifocal leukoencephalopathy: its pathological features. , 1983, Progress in clinical and biological research.

[17]  R. Ransohoff,et al.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function , 2009, Neurology.

[18]  J. Heritage,et al.  Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. , 1983, The Journal of infectious diseases.

[19]  S. Cepok,et al.  Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.

[20]  F. Nyberg,et al.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives , 2015, Therapeutic advances in neurological disorders.

[21]  J. Fagius,et al.  Normal outcome of pregnancy with ongoing treatment with natalizumab , 2014, Acta neurologica Scandinavica.

[22]  D. Centonze,et al.  Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids , 2014, CNS neuroscience & therapeutics.

[23]  R. Wilson.  MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study , 2015, Neurology.

[24]  L. Davis,et al.  Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. , 1990, Journal of immunology.

[25]  K. Baldwin,et al.  Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. , 2013, Current opinion in neurology.

[26]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[27]  M. Wenten,et al.  Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study , 2016, BMC Neurology.

[28]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[29]  E. Major,et al.  Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain , 2012, Clinical Microbiology Reviews.

[30]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[31]  V. Martinelli,et al.  Recurrence of disease activity after repeated Natalizumab withdrawals , 2015, Neurological Sciences.

[32]  V. Martinelli,et al.  Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. , 2014, Multiple sclerosis and related disorders.

[33]  P. Sørensen,et al.  Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients , 2014, Journal of Neurology.

[34]  F. Barkhof,et al.  POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS , 2008, Neurology.

[35]  J. Sejvar,et al.  PML diagnostic criteria , 2013, Neurology.

[36]  E. Trinka,et al.  From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch. , 2017, Clinical Immunology.

[37]  Matthew P. Anderson,et al.  Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons , 2009, Annals of neurology.

[38]  C. Sofia,et al.  Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis , 2015, BMJ Case Reports.

[39]  S. Misbah,et al.  Progressive multi‐focal leucoencephalopathy – driven from rarity to clinical mainstream by iatrogenic immunodeficiency , 2017, Clinical and experimental immunology.

[40]  H. Schroten,et al.  Natalizumab treatment during pregnancy – effects on the neonatal immune system , 2013, Acta neurologica Scandinavica.

[41]  Jacqueline Palace,et al.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  M. Trojano,et al.  Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients , 2016, Journal of Neurology.

[43]  I. Buraga,et al.  Multiple Sclerosis and Pregnancy: Current Considerations , 2014, TheScientificWorldJournal.

[44]  Allen J Aksamit,et al.  Progressive multifocal leukoencephalopathy , 2008, Continuum.

[45]  D. Evangelopoulos,et al.  Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod , 2016, The International journal of neuroscience.

[46]  A. Candeliere Merlicco,et al.  Observational Study of Switching from Natalizumab to Immunomodulatory Drugs , 2017, European Neurology.

[47]  D. Ramasamy,et al.  Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[48]  J. M. Scholtz,et al.  Osteopontin is a ligand for the α 4 β 1 integrin , 1998 .

[49]  E. Richardson.  Progressive multifocal leukoencephalopathy. , 1961, The New England journal of medicine.

[50]  R. Fox,et al.  The effect of plasma exchange on serum anti-JC virus antibodies , 2013, Multiple sclerosis.

[51]  C. Janeway,et al.  Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma , 1993, The Journal of experimental medicine.

[52]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[53]  R. Hughes.  Pathogenesis of multiple sclerosis. , 1992, Journal of the Royal Society of Medicine.

[54]  M. Elices,et al.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.

[55]  A. Bar-Or,et al.  GLANCE , 2009, Neurology.

[56]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.

[57]  D. Campagnolo,et al.  Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy , 2014, Annals of neurology.

[58]  K. Rammohan,et al.  WriteClick: Editor’s Choice DISEASE ACTIVITY RETURN DURING NATALIZUMAB TREATMENT INTERRUPTION IN PATIENTS WITH MULTIPLE SCLEROSIS , 2011 .

[59]  T. Flotte,et al.  Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines. , 1984, Journal of immunology.

[60]  Simone Faller,et al.  Th17 cells: A prognostic marker for MS rebound after natalizumab cessation? , 2017, Multiple sclerosis.

[61]  D. Centonze,et al.  Considerations on discontinuing natalizumab for the treatment of multiple sclerosis , 2010, Annals of neurology.

[62]  L. Kappos,et al.  Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study , 2014, Neurology.

[63]  E. Major,et al.  JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency , 1996, Journal of virology.

[64]  W. Brück,et al.  Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal , 2017, Multiple sclerosis.

[65]  F. Piehl,et al.  Rituximab versus fingolimod after natalizumab in multiple sclerosis patients , 2016, Annals of neurology.

[66]  J. Avasarala.  The TOUCH program and natalizumab: Fundamental flaw in patient protection , 2016, F1000Research.

[67]  H. Hartung,et al.  Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[68]  G. Comi,et al.  Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study , 2010, Neurological Sciences.

[69]  L. Kappos,et al.  Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[70]  N. Just,et al.  Progressive Multifocal Leukoencephalopathy with Gray Matter Involvement , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[71]  S. Hauser,et al.  Multiple sclerosis: Prospects and promise , 2013, Annals of neurology.

[72]  M. Hemler,et al.  The pathophysiologic role of alpha 4 integrins in vivo. , 1994, The Journal of clinical investigation.

[73]  N. Putzki,et al.  Review: Natalizumab in the treatment of multiple sclerosis , 2009, Therapeutic advances in neurological disorders.

[74]  M. Tullman,et al.  Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. , 2013, The American journal of managed care.

[75]  R. Gold,et al.  Natalizumab use during the third trimester of pregnancy. , 2014, JAMA neurology.

[76]  M. Sormani,et al.  Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). , 2014, JAMA neurology.

[77]  M. Clanet,et al.  Risk of relapse after natalizumab withdrawal , 2016, Neurology: Neuroimmunology & Neuroinflammation.